This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Campana D, Pui CH . Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 1995; 85: 1416–1434.
San Miguel JF, Martinez A, Macedo A, Vidriales MB, Lopez-Berges C, Gonzalez M et al. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 1997; 90:2465–2470.
Terstappen LW, Safford M, Konemann S, Loken MR, Zurlutter K, Buchner T et al. Flow cytometric characterization of acute myeloid leukemia. Part II. henotypic heterogeneity at diagnosis. Leukemia 1992; 6: 70–80.
Venditti A, Buccisano F, Del Poeta G, Maurillo L, Tamburini A, Cox C, Battaglia A et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000; 96: 3948–3952.
San Miguel JF, Vidriales MB, Lopez-Berges C, Diaz-Mediavilla J, Gutierrez N, Canizo C et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001; 98: 1746–1751.
San Miguel JF, Ciudad J, Vidriales MB, Orfao A, Lucio P, Porwit-MacDonald A et al. Immunophenotypical detection of minimal residual disease in acute leukemia. Crit Rev Oncol Hematol 1999; 32: 175–185.
Macedo A, Orfao A, Ciudad J, Gonzalez M, Vidriales B, Lopez-Berges MC et al. Phenotypic analysis of CD34 subpopulations in normal human bone marrow and its application for the detection of minimal residual disease. Leukemia 1995; 9: 1896–1901.
Yin JA, Tobal K . Detection of minimal residual disease in acute myeloid leukemia: methodologies,clinical and biological significance. Br J Haematol 1999; 106: 578–590.
Scolnik MP, Morilla R, de Bracco MM, Catovsky D, Matutes E . CD34 and CD117 are overexpressed in AML and may be valuable to detect minimal residual disease. Leukemia Res 2002; 26: 615–619.
Rights and permissions
About this article
Cite this article
van Stijn, A., Kok, A., van der Pol, M. et al. Multiparameter flow cytometric quantification of apoptosis-related protein expression. Leukemia 17, 787–788 (2003). https://doi.org/10.1038/sj.leu.2402886